BeiGene stock (US07725L1026): BEQALZI receives US FDA accelerated approval

BeiGene announced accelerated FDA approval for BEQALZI (Sotokela), marking a significant milestone for the Swiss oncology company's pipeline. The stock traded near $218 on May 13, 2026.

BeiGene, a global oncology company domiciled in Switzerland, announced that BEQALZI (Sotokela) has received accelerated approval from the U.S. Food and Drug Administration, according to AAStocks as of May 13, 2026. This regulatory milestone represents a key validation of the company's oncology pipeline and expands its portfolio of approved treatments targeting cancer patients worldwide.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: BeiGene Ltd
• Sector/industry: Oncology/Biopharmaceuticals
• Headquarters/country: Switzerland
• Core markets: Global oncology, cancer treatment
• Key revenue drivers: Innovative cancer therapies, approved and pipeline products
• Home exchange/listing venue: Nasdaq (ONC); also listed on Hong Kong Exchange (06160.HK)
• Trading currency: USD (Nasdaq)

BeiGene: global oncology innovator

BeiGene is a global oncology company discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. The company operates across multiple geographies and maintains a diversified pipeline of novel therapeutics targeting well-established oncogenic drivers in solid tumors and hematologic malignancies. The accelerated FDA approval of BEQALZI represents validation of the company's scientific approach and regulatory strategy in bringing new treatment options to market.

Main revenue and product drivers for BeiGene

BeiGene's pipeline includes multiple clinical-stage programs targeting high-prevalence cancers. Key programs include BG-C0902, which targets Epidermal Growth Factor Receptor (EGFR) and cellular-Mesenchymal Epithelial Transition (cMET) using an antibody-drug conjugate modality, and BG-T187, an engineered antibody targeting the same oncogenic drivers. These dual-targeting approaches are designed to address dysregulation frequently observed in lung cancers and other solid tumors, potentially offering durable response and broad patient coverage.

Conclusion

The FDA accelerated approval of BEQALZI marks a significant regulatory achievement for BeiGene and validates the company's oncology development strategy. As a Nasdaq-listed company with substantial market capitalization and global reach, BeiGene continues to advance its pipeline of innovative cancer treatments. The approval expands the company's commercial portfolio and reinforces its position in the competitive global oncology market, though investors should monitor ongoing clinical development, competitive dynamics, and regulatory outcomes for the broader pipeline.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.